Synonyms
Definition
Colorectal tumors are developed from colorectal mucosae. They are mostly adenocarcinomas arising from precancerous lesion known as adenomatous polyp. The transformation from an adenomatous polyp to a malignant adenocarcinoma takes most often several years. The adenocarcinomas are classified as stage I tumor limited to muscularis layer, stage II tumor limited to serosa, stage III tumor with regional lymph node metastasis, and stage IV tumor with distant metastasis. The treatment is adapted according to tumor stage.
Overview
Colorectal Cancer (CRC) is one of the most frequent cancers. Currently, in Europe and the USA, the median age of CRC diagnosis is 70 years (Ferlay et al. 2013; Siegel et al. 2016). The specific questions about age arise mainly after 75 years. Given the ageing of the population, the proportion of patients with CRC aged over 75 years will increase even further in the coming years. Unfortunately, the...
This is a preview of subscription content, log in via an institution.
References
Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351. https://doi.org/10.1056/NEJMoa032709
André T, Vernerey D, Mineur L et al (2018) Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol 36:1469–1477. https://doi.org/10.1200/JCO.2017.76.0355
Aparicio T, Desrame J, Lecomte T et al (2003) Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 89:1439–1444. https://doi.org/10.1038/sj.bjc.6601310
Aparicio T, Navazesh A, Boutron I et al (2009) Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 71:249–257. https://doi.org/10.1016/j.critrevonc.2008.11.006
Aparicio T, Schischmanoff O, Poupardin C et al (2013a) Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Dig Liver Dis 45:245–250. https://doi.org/10.1016/j.dld.2012.09.013
Aparicio T, Jouve JL, Teillet L et al (2013b) Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 31:1464–1470. https://doi.org/10.1200/JCO.2012.42.9894
Aparicio T, Schischmanoff O, Poupardin C et al (2014) High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. J Geriatr Oncol 5:384–388. https://doi.org/10.1016/j.jgo.2014.08.002
Aparicio T, Pamoukdjian F, Quero L et al (2016a) Colorectal cancer care in elderly patients: unsolved issues. Dig Liver Dis 48:1112–1118. https://doi.org/10.1016/j.dld.2016.05.011
Aparicio T, Francois E, Cristol-Dalstein L et al (2016b) PRODIGE 340-FFCD 1402-ADAGE: adjuvant chemotherapy in elderly patients with resected stage III colon cancer. A randomized phase 3 trial. Dig Liver Dis 48:206–207. https://doi.org/10.1016/j.dld.2015.11.023
Aparicio T, Lavau-Denes S, Phelip JM et al (2016c) Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol 27:121–127. https://doi.org/10.1093/annonc/mdv491
Aparicio T, Gargot D, Teillet L et al (2017) Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer 74:98–108. https://doi.org/10.1016/j.ejca.2016.09.029
Aparicio T, Bouché O, Taieb J et al (2018a) Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial – PRODIGE 20 study results. Ann Oncol 29:133–138. https://doi.org/10.1093/annonc/mdx529
Aparicio T, Bouché O, Francois E et al (2018b) Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. Eur J Cancer 97:16–24. https://doi.org/10.1016/j.ejca.2018.03.030
Aparicio T, Darut-Jouve A, Khemissa Akouz F et al (2020a) Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD. J Geriatr Oncol. S1879-4068(19)30500-4. https://doi.org/10.1016/j.jgo.2020.04.001
Aparicio T, Canouï-Poitrine F, Caillet P et al (2020b) Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). Dig Liver Dis 52:493–505. https://doi.org/10.1016/j.dld.2019.12.145
Bellera CA, Rainfray M, Mathoulin-Pelissier S et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166–2172. https://doi.org/10.1093/annonc/mdr587
Bouvier AM, Launoy G, Lepage C et al (2005) Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther 22:233–241. https://doi.org/10.1111/j.1365-2036.2005.02559.x
Cassidy J, Saltz LB, Giantonio BJ et al (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136:737–743. https://doi.org/10.1007/s00432-009-0712-3
Chan M, Hugh-Yeun K, Gresham G et al (2017) Population-based patterns and factors associated with underuse of palliative systemic therapy in elderly patients with metastatic colon cancer. Clin Colorectal Cancer 16:147–153. https://doi.org/10.1016/j.clcc.2016.08.004
Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077–1085. https://doi.org/10.1016/S1470-2045(13)70154-2
Doat S, Thiebaut A, Samson S et al (2014) Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer 50:1276–1283. https://doi.org/10.1016/j.ejca.2013.12.026
Douillard J, Siena S, Peeters M et al (2014) Impact of baseline age on efficacy and safety of first-line panitumumab (pmab) + FOLFOX4 vs FOLFOX4 treatment. Ann Oncol 25(Suppl 4):547P
Extermann M, Boler I, Reich RR (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377–3386. https://doi.org/10.1002/cncr.26646
Faivre-Finn C, Bouvier AM, Mitry E et al (2002) Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Aliment Pharmacol Ther 16:353–359. https://doi.org/10.1046/j.1365-2036.2002.01187.x
Ferlay J, Teliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027
Folprecht G, Cunningham D, Ross P et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330–1338. https://doi.org/10.1093/annonc/mdh344
Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:1443–1451. https://doi.org/10.1200/JCO.2007.14.0509
Folprecht G, Köhne C, Bokemeyer C et al (2010) Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer: a pooled analysis of the CRISTAL and OPUS studies. Ann Oncol [European Cancer Congress] A597
Fornaro L, Baldi GG, Masi G et al (2011) Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. Crit Rev Oncol Hematol 78:243–251. https://doi.org/10.1016/j.critrevonc.2010.06.003
Francois E, Berdah JF, Chamorey E et al (2008) Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a phase II study. Cancer Chemother Pharmacol 62:931–936. https://doi.org/10.1007/s00280-008-0681-2
Frerot M, Jooste V, Binquet C et al (2015) Factors influencing inclusion in digestive cancer clinical trials: a population-based study. Dig Liver Dis 47:891–896. https://doi.org/10.1016/j.dld.2015.05.017
Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091. https://doi.org/10.1200/JCO.2006.06.9039
Gouverneur A, Claraz P, Rousset M et al (2017) Comparative safety of targeted therapies for metastatic colorectal cancer between elderly and younger patients: a study using the international pharmacovigilance database. Target Oncol 12:805–814. https://doi.org/10.1007/s11523-017-0529-y
Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177–1188. https://doi.org/10.1056/NEJMoa1713709
Haller D, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471. https://doi.org/10.1200/JCO.2010.33.6297
Hamaker ME, Jonker JM, de Rooij SE et al (2012) Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 13:e437–e444. https://doi.org/10.1016/S1470-2045(12)70259-0
Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465. https://doi.org/10.1200/JCO.2011.34.7625
Jehn CF, Boning L, Kroning H et al (2014) Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. Eur J Cancer 50:1269–1275. https://doi.org/10.1016/j.ejca.2014.01.005
Jung B, Pahlman L, Johansson R et al (2009) Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995–2004. BMC Cancer 9:68. https://doi.org/10.1186/1471-2407-9-68
Köhne C, Cunningham D, Di Costanzo F et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308–317. https://doi.org/10.1093/annonc/mdf034
Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862–870. https://doi.org/10.1634/theoncologist.2009-0071
Kwakman JJM, Simkens LHJ, van Rooijen JM et al (2017) Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol 28:1288–1293. https://doi.org/10.1093/annonc/mdx122
Landre T, Uzzan B, Nicolas P et al (2015) Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. A meta-analysis. Int J Color Dis 30:1305–1310. https://doi.org/10.1007/s00384-015-2296-5
Landre T, Maillard E, Taleb C et al (2018) Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Color Dis 33:1125–1130. https://doi.org/10.1007/s00384-018-3053-3
Laurent M, Des Guetz G, Bastuji-Garin S et al (2018) Chronological age and risk of chemotherapy nonfeasibility: a real-life cohort study of 153 stage II or III colorectal cancer patients given adjuvant-modified FOLFOX6. Am J Clin Oncol 41:73–80. https://doi.org/10.1097/COC.0000000000000233
Lievre A, Laurent V, Cudennec T et al (2014) Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral Centre. Dig Liver Dis 46:838–845. https://doi.org/10.1016/j.dld.2014.05.005
Liuu E, Canoui-Poitrine F, Tournigand C et al (2014) Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol 5:11–19. https://doi.org/10.1016/j.jgo.2013.08.003
Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640. https://doi.org/10.1200/JCO.2011.37.7176
Mahoney T, Kuo YH, Topilow A et al (2000) Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135:182–185. https://doi.org/10.1001/archsurg.135.2.182
Manceau G, Karoui M, Werner A et al (2012) Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. Lancet Oncol 13:e525–e536. https://doi.org/10.1016/S1470-2045(12)70378-9
Margalit DN, Mamon HJ, Ancukiewicz M et al (2011) Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys 81:e735–e741. https://doi.org/10.1016/j.ijrobp.2010.12.056
Martijn H, Vulto JC (2007) Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer 43:2301–2306. https://doi.org/10.1016/j.ejca.2007.06.014
McCleary NJ, Meyerhardt JA, Green E et al (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 31:2600–2606. https://doi.org/10.1200/JCO.2013.49.6638
O’Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381–3388. https://doi.org/10.1200/JCO.2010.34.3426
Olsson LI, Granstrom F, Glimelius B (2011) Socioeconomic inequalities in the use of radiotherapy for rectal cancer: a nationwide study. Eur J Cancer 47:347–353. https://doi.org/10.1016/j.ejca.2010.03.015
Paillaud E, Liuu E, Laurent M et al (2014) Geriatric syndromes increased the nutritional risk in elderly cancer patients independently from tumour site and metastatic status. The ELCAPA-05 cohort study. Clin Nutr 33:330–335. https://doi.org/10.1016/j.clnu.2013.05.014
Pamoukdjian F, Aparicio T, Zebachi S et al (2020) Comparison of mobility indices for predicting early death in older patients with cancer: the PF-EC cohort study. J Gerontol A Biol Sci Med Sci 75:189–196. https://doi.org/10.1093/gerona/glz024
Papamichael D, Audisio RA, Glimelius B et al (2015) Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26:463–476. https://doi.org/10.1093/annonc/mdu253
Petrioli R, Chirra M, Messuti L et al (2018) Efficacy and safety of regorafenib with 2/1 schedule for patients ≥ 75 years with metastatic colorectal cancer after failure of 2 lines of chemotherapy. Clin Colorectal Cancer 17:307–312. https://doi.org/10.1016/j.clcc.2018.02.005
Pietrantonio F, Cremolini C, Aprile G et al (2015) Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist 20:1261–1265. https://doi.org/10.1016/j.clcc.2018.02.005
Price TJ, Zannino D, Wilson K et al (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 23:1531–1536. https://doi.org/10.1093/annonc/mdr488
Quarini C, Gosney M (2009) Review of the evidence for a colorectal cancer screening programme in elderly people. Age Ageing 38:503–508. https://doi.org/10.1093/ageing/afp103
Quasar Collaborative Group, Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029. https://doi.org/10.1016/S0140-6736(07)61866-2
Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257. https://doi.org/10.1056/NEJMoa022289
Rosati G, Aprile G, Cardellino GG et al (2016) A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 7:134–141. https://doi.org/10.1016/j.jgo.2016.01.006
Rutten HJ, den Dulk M, Lemmens VE et al (2008) Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9:494–501. https://doi.org/10.1016/S1470-2045(08)70129-3
Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097. https://doi.org/10.1056/NEJMoa010957
Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219–3226. https://doi.org/10.1200/JCO.2009.27.1825
Sastre J, Aranda E, Gravalos C et al (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 77:78–84. https://doi.org/10.1016/j.critrevonc.2009.11.005
Sastre J, Gravalos C, Rivera F et al (2012) First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 17:339–345. https://doi.org/10.1634/theoncologist.2011-0406
Sastre J, Massuti B, Pulido G et al (2015) First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 51:1371–1380. https://doi.org/10.1016/j.ejca.2015.04.013
Seymour MT, Thompson LC, Wasan HS et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749–1759. https://doi.org/10.1016/S0140-6736(11)60399-1
Shankaran V, Mummy D, Koepl L et al (2013) Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer. Clin Colorectal Cancer 12:204–213.e1. https://doi.org/10.1016/j.clcc.2012.11.004
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics 2016. Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21590
Sorbye H, Pfeiffer P, Cavalli-Bjorkman N et al (2009) Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115:4679–4687. https://doi.org/10.1002/cncr.24527
Soubeyran P, Fonck M, Blanc-Bisson C et al (2012) Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 30:1829–1834. https://doi.org/10.1200/JCO.2011.35.7442
Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring the quality of life of cancer patients a concise QL-index for use by physicians. J Chronic Dis 34:585–597. https://doi.org/10.1016/0021-9681(81)90058-8
Tournigand C, Andre T, Bonnetain F et al (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30:3353–3360. https://doi.org/10.1200/JCO.2012.42.5645
Van Cutsem E, Peeters M, Siena S et al (2007) A phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. Proceedings of ASCO GI Cancer Symposium, A349
Van Cutsem E, Sobrero A, Siena S et al (2013) Regorafenib in progressive metastatic colorectal cancer: analysis of age subgroups in the phase III CORRECT trial. J Clin Oncol 31(suppl):A3636
Van Cutsem E, Mayer RJ, Laurent S et al (2018) The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 90:63–72. https://doi.org/10.1016/j.ejca.2017.10.009
Van den Broek CB, Bastiaannet E, Dekker JW (2013) Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008. Acta Oncol 52:941–949. https://doi.org/10.3109/0284186X.2012.739730
Van Erning FN, Janssen-Heijnen ML, Creemers GJ et al (2017) Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy. Int J Cancer 140:224–233. https://doi.org/10.1002/ijc.30423
Winther SB, Liposits G, Skuladottir H et al (2019) Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol 4:376–388. https://doi.org/10.1016/S2468-1253(19)30041-X
Yee KW, Pater JL, Pho L et al (2003) Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 21:1618–1623. https://doi.org/10.1200/JCO.2003.12.044
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Aparicio, T. (2020). Tumors: Colorectal. In: Gu, D., Dupre, M. (eds) Encyclopedia of Gerontology and Population Aging. Springer, Cham. https://doi.org/10.1007/978-3-319-69892-2_776-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-69892-2_776-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-69892-2
Online ISBN: 978-3-319-69892-2
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences